Top 5 Infectious Disease Stories of the Week-April 1, 2022

Article

Here is a rundown of the most popular stories we covered this past week.


Here is an opportunity to catch-up with some of the important stories we have been covering this week.

Contagion compiles 5 highlights of our coverage in infectious disease including video interviews, podcasts, and significant stories from the week ending April 1, 2022.

Here are Contagion’s highlights from the week:

1. First Study to Estimate Life Expectancy After COVID-19 Pandemic Finds 2 Years Lost
The coronavirus pandemic caused the first global recorded decline in human life expectancy.


2. Pfizer-BioNTech and Moderna mRNA Vaccines Elicit Different Antibody Responses
 The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.

3. FDA Amends Authorization for Second Booster Dose for mRNA COVID-19 Vaccines
The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.


4. NIH Launches Trial Evaluating Second COVID-19 Booster Shots
One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.


5. Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.